Increased risk of hyperkalaemia w/ aliskiren, K-salts, K-sparing diuretics (eg, eplerenone, spironolactone), ACE inhibitors, AIIA, NSAIDs, heparins, immunosuppressants eg, ciclosporine or tacrolimus, trimethoprim, co-trimoxazole. Increased risk of severe anaphylactoid reactions w/ extracorporeal treatments. Increased risk of angioedema w/ sacubitril/valsartan, estramustine, racecadotril, mTOR inhibitors eg, sirolimus, everolimus, temsirolimus; gliptins eg, linagliptin, saxagliptin, sitagliptin, vildagliptin. Increased risk of leucopenia w/ allopurinol, cytostatic or immunosuppressive agents, systemic corticosteroids or procainamide. Increased antihypertensive effect & risk of orthostatic hypotension w/ imipramine-like antidepressants eg, TCAs, neuroleptics. Additive effect w/ IV amphotericin B, gluco- & mineralocorticoids (systemic route), tetracosactide, stimulant laxatives. Additive BP-lowering effect w/ other antihypertensives. Reduced antihypertensive effect w/ corticosteroids, tetracosactide; sympathomimetics. Reversible increased in serum conc & toxicity of lithium. Increased risk of worsened renal function & CV morbidity & mortality w/ aliskiren. Higher frequency of hypotension, syncope, hyperkalaemia & worsened renal function w/ angiotensin-receptor blocker. Additive hyperkalaemic effect w/ K-sparing drugs eg, triamterene, amiloride; K-salts. Increased antihypertensive effects w/ baclofen. Attenuated antihypertensive effects w/ NSAIDs eg, acetylsalicylic acid, COX-2 inhibitors & non-selective NSAIDs. Increased risk of acute renal failure w/ NSAIDs. Increased blood-glucose lowering effects w/ risk of hypoglycaemia w/ antidiabetics eg, insulin, oral hypoglycemics. Reduced hypotensive effects w/ non-K-sparing diuretics. Reduced BP w/ nitroglycerin & other nitrates or vasodilators. Lethal ventricular fibrillation & CV collapse w/ verapamil & dantrolene infusion. Increased bioavailability w/ grapefruit or grapefruit juice. Risk of hypokalaemia w/ Torsade de pointes-inducing drugs. Favoured toxic effects of cardiac glucosides w/ low K levels. Significant increased exposure w/ CYP3A4 inhibitors eg, PIs, azole antifungals, macrolides (eg, erythromycin or clarithromycin), verapamil, diltiazem. Increased risk of hypotension w/ clarithromycin. Enhanced hypotensive effects of anaesth. Vol depletion & risk of hypotension w/ thiazide or loop diuretics. Nitritoid reactions w/ injectable gold (Na aurothiomalate). Lactic acidosis may occur w/ metformin. Increased risk of acute renal insufficiency w/ high-dose iodinated contrast media. May increase levels of Ca. Increased creatinine level w/ ciclosporine. May increase blood levels of tacrolimus. May increase exposure of mTOR inhibitors & simvastatin.